Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: FNS who wrote (682)	5/28/1998 6:07:00 PM
From: Donaldm	Read Replies (2) \| Respond to of 965

This will give you a better idea of the approval: Reuters, Thursday, May 28, 1998 at 17:45 WASHINGTON, May 28 (Reuters) - A Food and Drug Administration advisory panel Thursday recommended approval of a drug for treating the intestinal inflammation caused by Crohn's disease. The FDA's gastrointestinal drugs committee found that Avakine, to be marketed by Centocor Inc (NASDAQ:CNTO),was effective in reducing abscesses and fistulas, or small holes,in the intestine wall. Avakine is a monoclonal antibody treatment that moderate the inflammatory response of cells in the gastric tract. The advisory panel recommended the therapy for treatment of moderate to severe Crohn's disease despite some reservations about its long-term effectiveness. The FDA is not bound by the opinions of its advisory panel but usually follows them. "The data is quite good in my mind that it works acutely (initially)," said panel member Loren Laine, a professor of medicine at the University of Southern California. ÿ